Supplementary Table 3.
Univariable logistic regression for analyzing the risk factors for developing distant metastases in patients with gastric cancer.
| Subject characteristics | M-Met | Liver-Met | Lung-Met | Bone-Met | Brain-Met | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Age | ||||||||||
| <65 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| ≥65 | 0.65 (0.62–0.67) | <0.001 | 0.92 (0.87–0.98) | 0.007 | 0.87 (0.79–0.96) | 0.005 | 0.63 (0.57–0.70) | <0.001 | 0.57 (0.44–0.74) | <0.001 |
| Gender | ||||||||||
| Male | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| Female | 0.83 (0.79–0.87) | <0.001 | 0.61 (0.57–0.65) | <0.001 | 0.72 (0.65–0.80) | <0.001 | 0.79 (0.71–0.88) | <0.001 | 0.59 (0.44–0.79) | <0.001 |
| Race | ||||||||||
| White | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| Black | 0.96 (0.90–1.02) | 0.193 | 1.18 (1.08–1.27) | <0.001 | 0.80 (0.69–0.93) | 0.004 | 0.71 (0.60–0.84) | <0.001 | 0.51 (0.32–0.81) | 0.005 |
| Others | 0.86 (0.81–0.92) | <0.001 | 0.74 (0.68–0.81) | <0.001 | 0.75 (0.65–0.87) | <0.001 | 0.87 (0.75–1.02) | 0.080 | 0.54 (0.34–0.84) | 0.007 |
| Marital status | ||||||||||
| Married | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| Unmarried | 0.96 (0.92–1.01) | 0.121 | 0.97 (0.92–1.04) | 0.392 | 1.06 (0.96–1.17) | 0.279 | 0.99 (0.89–1.10) | 0.841 | 0.92 (0.70–1.21) | 0.548 |
| Insurance status | ||||||||||
| Insured | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| Uninsured | 1.93 (1.73–2.16) | <0.001 | 1.36 (1.18–1.56) | <0.001 | 1.45 (1.16–1.81) | 0.001 | 1.50 (1.19–1.90) | 0.001 | 1.61 (0.92–2.83) | 0.096 |
| Primary site | ||||||||||
| Proximal third | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| Mid | 0.87 (0.81–0.94) | 0.001 | 0.57 (0.51–0.63) | <0.001 | 0.47 (0.39–0.57) | <0.001 | 0.76 (0.63–0.91) | 0.003 | 0.27 (0.15–0.50) | <0.001 |
| Distal third | 0.74 (0.69–0.79) | <0.001 | 0.52 (0.47–0.56) | <0.001 | 0.40 (0.34–0.47) | <0.001 | 0.46 (0.39–0.55) | <0.001 | 0.17 (0.10–0.31) | <0.001 |
| Stomach, NOS | 1.07 (1.01–1.13) | 0.020 | 0.67 (0.62–0.72) | <0.001 | 0.71 (0.63–0.79) | <0.001 | 0.90 (0.79–1.02) | 0.089 | 0.61 (0.45–0.82) | 0.001 |
| Overlapping | 1.40 (1.28–1.52) | <0.001 | 0.70 (0.62–0.79) | <0.001 | 0.69 (0.57–0.85) | <0.001 | 0.80 (0.64–0.99) | 0.037 | 0.26 (0.12–0.56) | 0.001 |
| Histology | ||||||||||
| Adenocar-cinoma | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| Mucous carcinoma | 1.00 (0.84–1.19) | 0.977 | 0.57 (0.44–0.74) | <0.001 | 1.06 (0.74–1.50) | 0.760 | 0.96 (0.63–1.47) | 0.856 | 0.48 (0.12–1.93) | 0.300 |
| Signet-ring cell carcinoma | 1.31 (1.24–1.39) | <0.001 | 0.29 (0.26–0.33) | <0.001 | 0.75 (0.66–0.87) | <0.001 | 1.63 (1.44–1.84) | <0.001 | 0.92 (0.65–1.31) | 0.640 |
| Unknown | 0.46 (0.43–0.49) | <0.001 | 0.66 (0.61–0.71) | <0.001 | 0.51 (0.44–0.59) | <0.001 | 0.45 (0.37–0.54) | <0.001 | 0.47 (0.30–0.72) | 0.001 |
| Grade | ||||||||||
| I | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| II | 4.22 (3.66–4.87) | <0.001 | 4.32 (3.60–5.19) | <0.001 | 3.52 (2.57–4.83) | <0.001 | 4.42 (2.65–7.39) | <0.001 | 20.42 (2.82–147.80) | 0.003 |
| III | 7.04 (6.15–8.07) | <0.001 | 3.62 (3.03–4.33) | <0.001 | 3.60 (2.65–4.88) | <0.001 | 10.32 (6.29–16.95) | <0.001 | 17.68 (2.47–126.74) | 0.004 |
| IV | 5.46 (4.44–6.71) | <0.001 | 4.07 (3.12–5.30) | <0.001 | 2.16 (1.28–3.62) | 0.004 | 5.71 (2.96–10.99) | <0.001 | 29.97 (3.68–243.96) | 0.001 |
| T stage | ||||||||||
| T1 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| T2 | 0.63 (0.57–0.69) | <0.001 | 0.41 (0.35–0.48) | <0.001 | 0.38 (0.29–0.50) | <0.001 | 0.46 (0.34–0.62) | <0.001 | 0.52 (0.25–1.08) | 0.078 |
| T3 | 0.88 (0.82–0.94) | <0.001 | 0.65 (0.58–0.72) | <0.001 | 0.57 (0.48–0.68) | <0.001 | 0.77 (0.64–0.93) | 0.007 | 0.75 (0.46–1.22) | 0.248 |
| T4 | 2.40 (2.24–2.58) | <0.001 | 1.42 (1.29–1.55) | <0.001 | 1.27 (1.08–1.48) | 0.003 | 1.15 (0.96–1.38) | 0.141 | 0.95 (0.58–1.57) | 0.853 |
| N stage | ||||||||||
| N0 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 | 1.00 (Reference) | 1.00 |
| N1 | 2.79 (2.65–2.95) | <0.001 | 2.52 (2.35–2.70) | <0.001 | 2.49 (2.23–2.79) | <0.001 | 2.64 (2.34–2.98) | <0.001 | 2.49 (1.83–3.40) | <0.001 |
| N2 | 0.95 (0.87–1.05) | 0.320 | 0.83 (0.73–0.95) | 0.008 | 0.74 (0.57–0.95) | 0.017 | 0.82 (0.63–1.07) | 0.150 | 0.90 (0.46–1.73) | 0.743 |
| N3 | 1.06 (0.97–1.17) | 0.196 | 0.72 (0.62–0.84) | <0.001 | 0.74 (0.58–0.96) | 0.023 | 0.84 (0.65–1.10) | 0.210 | 1.21 (0.67–2.18) | 0.523 |
Met – metastases; OR – odds ratio; CI – confidence interval; NOS – not otherwise specified.